Eintrag weiter verarbeiten
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis: A PRISMA-compliant meta-analysis
Gespeichert in:
| Zeitschriftentitel: | Medicine |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Medicine, 98, 2019, 2, S. e14091 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Li, Jialin Cheng, Yusheng Ji, Zhigang Li, Jialin Cheng, Yusheng Ji, Zhigang |
|---|---|
| author |
Li, Jialin Cheng, Yusheng Ji, Zhigang |
| spellingShingle |
Li, Jialin Cheng, Yusheng Ji, Zhigang Medicine Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis General Medicine |
| author_sort |
li, jialin |
| spelling |
Li, Jialin Cheng, Yusheng Ji, Zhigang 0025-7974 1536-5964 Ovid Technologies (Wolters Kluwer Health) General Medicine http://dx.doi.org/10.1097/md.0000000000014091 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>The prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in patients with urologic tumors remains controversial. Therefore, we herein conducted a meta-analysis to systematically assess the prognostic value of LMR in patients with urologic tumors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We comprehensively searched PubMed, EMBASE and Web of Science to identify eligible studies. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the prognostic value of LMR in patients with urologic tumors. This meta-analysis was registered in PROSPERO (CRD42018108959).</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>A total of 20 studies were included in this meta-analysis. Our synthesized analysis showed that low LMR was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in patients with upper tract urothelial cancer (UTUC). We also found that renal cell cancer (RCC) patients with low LMR had poor OS, PFS and cancer-specific survival (CSS). Besides, it was observed that low LMR predicted poor OS, RFS and CSS in patients with bladder cancer (BC).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>This meta-analysis demonstrated that pretreatment LMR is associated with survival, and may be a useful prognostic parameter in urologic tumors. Nevertheless, more prospective and heterogeneous studies with large samples are required to further confirm our findings before it is applied for daily clinical decision making.</jats:p> </jats:sec> A PRISMA-compliant meta-analysis Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis Medicine |
| doi_str_mv |
10.1097/md.0000000000014091 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE0MDkx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE0MDkx |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2019 |
| issn |
0025-7974 1536-5964 |
| issn_str_mv |
0025-7974 1536-5964 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
li2019prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithurologictumorsaprismacompliantmetaanalysisaprismacompliantmetaanalysis |
| publishDateSort |
2019 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Medicine |
| source_id |
49 |
| title_sub |
A PRISMA-compliant meta-analysis |
| title |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_unstemmed |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_full |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_fullStr |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_full_unstemmed |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_short |
Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_sort |
prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : a prisma-compliant meta-analysis |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1097/md.0000000000014091 |
| publishDate |
2019 |
| physical |
e14091 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>The prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in patients with urologic tumors remains controversial. Therefore, we herein conducted a meta-analysis to systematically assess the prognostic value of LMR in patients with urologic tumors.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>We comprehensively searched PubMed, EMBASE and Web of Science to identify eligible studies. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the prognostic value of LMR in patients with urologic tumors. This meta-analysis was registered in PROSPERO (CRD42018108959).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>A total of 20 studies were included in this meta-analysis. Our synthesized analysis showed that low LMR was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in patients with upper tract urothelial cancer (UTUC). We also found that renal cell cancer (RCC) patients with low LMR had poor OS, PFS and cancer-specific survival (CSS). Besides, it was observed that low LMR predicted poor OS, RFS and CSS in patients with bladder cancer (BC).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>This meta-analysis demonstrated that pretreatment LMR is associated with survival, and may be a useful prognostic parameter in urologic tumors. Nevertheless, more prospective and heterogeneous studies with large samples are required to further confirm our findings before it is applied for daily clinical decision making.</jats:p>
</jats:sec> |
| container_issue |
2 |
| container_start_page |
0 |
| container_title |
Medicine |
| container_volume |
98 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334999809163269 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:37:14.671Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prognostic+value+of+pretreatment+lymphocyte-to-monocyte+ratio+in+patients+with+urologic+tumors+%3A+A+PRISMA-compliant+meta-analysis&rft.date=2019-01-01&genre=article&issn=1536-5964&volume=98&issue=2&pages=e14091&jtitle=Medicine&atitle=Prognostic+value+of+pretreatment+lymphocyte-to-monocyte+ratio+in+patients+with+urologic+tumors+%3A+A+PRISMA-compliant+meta-analysis&aulast=Ji&aufirst=Zhigang&rft_id=info%3Adoi%2F10.1097%2Fmd.0000000000014091&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334999809163269 |
| author | Li, Jialin, Cheng, Yusheng, Ji, Zhigang |
| author_facet | Li, Jialin, Cheng, Yusheng, Ji, Zhigang, Li, Jialin, Cheng, Yusheng, Ji, Zhigang |
| author_sort | li, jialin |
| container_issue | 2 |
| container_start_page | 0 |
| container_title | Medicine |
| container_volume | 98 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>The prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in patients with urologic tumors remains controversial. Therefore, we herein conducted a meta-analysis to systematically assess the prognostic value of LMR in patients with urologic tumors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We comprehensively searched PubMed, EMBASE and Web of Science to identify eligible studies. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the prognostic value of LMR in patients with urologic tumors. This meta-analysis was registered in PROSPERO (CRD42018108959).</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>A total of 20 studies were included in this meta-analysis. Our synthesized analysis showed that low LMR was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in patients with upper tract urothelial cancer (UTUC). We also found that renal cell cancer (RCC) patients with low LMR had poor OS, PFS and cancer-specific survival (CSS). Besides, it was observed that low LMR predicted poor OS, RFS and CSS in patients with bladder cancer (BC).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>This meta-analysis demonstrated that pretreatment LMR is associated with survival, and may be a useful prognostic parameter in urologic tumors. Nevertheless, more prospective and heterogeneous studies with large samples are required to further confirm our findings before it is applied for daily clinical decision making.</jats:p> </jats:sec> |
| doi_str_mv | 10.1097/md.0000000000014091 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE0MDkx |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2019 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2019 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0025-7974, 1536-5964 |
| issn_str_mv | 0025-7974, 1536-5964 |
| language | English |
| last_indexed | 2024-03-01T14:37:14.671Z |
| match_str | li2019prognosticvalueofpretreatmentlymphocytetomonocyteratioinpatientswithurologictumorsaprismacompliantmetaanalysisaprismacompliantmetaanalysis |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | e14091 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Medicine |
| source_id | 49 |
| spelling | Li, Jialin Cheng, Yusheng Ji, Zhigang 0025-7974 1536-5964 Ovid Technologies (Wolters Kluwer Health) General Medicine http://dx.doi.org/10.1097/md.0000000000014091 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>The prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in patients with urologic tumors remains controversial. Therefore, we herein conducted a meta-analysis to systematically assess the prognostic value of LMR in patients with urologic tumors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We comprehensively searched PubMed, EMBASE and Web of Science to identify eligible studies. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the prognostic value of LMR in patients with urologic tumors. This meta-analysis was registered in PROSPERO (CRD42018108959).</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>A total of 20 studies were included in this meta-analysis. Our synthesized analysis showed that low LMR was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in patients with upper tract urothelial cancer (UTUC). We also found that renal cell cancer (RCC) patients with low LMR had poor OS, PFS and cancer-specific survival (CSS). Besides, it was observed that low LMR predicted poor OS, RFS and CSS in patients with bladder cancer (BC).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>This meta-analysis demonstrated that pretreatment LMR is associated with survival, and may be a useful prognostic parameter in urologic tumors. Nevertheless, more prospective and heterogeneous studies with large samples are required to further confirm our findings before it is applied for daily clinical decision making.</jats:p> </jats:sec> A PRISMA-compliant meta-analysis Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis Medicine |
| spellingShingle | Li, Jialin, Cheng, Yusheng, Ji, Zhigang, Medicine, Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis, General Medicine |
| title | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_full | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_fullStr | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_full_unstemmed | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_short | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| title_sort | prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : a prisma-compliant meta-analysis |
| title_sub | A PRISMA-compliant meta-analysis |
| title_unstemmed | Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors : A PRISMA-compliant meta-analysis |
| topic | General Medicine |
| url | http://dx.doi.org/10.1097/md.0000000000014091 |